BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25605370)

  • 41. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 42. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
    Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
    J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
    Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
    Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
    Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
    Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.
    Sallmyr A; Fan J; Datta K; Kim KT; Grosu D; Shapiro P; Small D; Rassool F
    Blood; 2008 Mar; 111(6):3173-82. PubMed ID: 18192505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nuclear factor of activated T-cells, NFATC1, governs FLT3
    Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
    J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
    Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
    Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
    Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
    Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).
    Rosen DB; Minden MD; Kornblau SM; Cohen A; Gayko U; Putta S; Woronicz J; Evensen E; Fantl WJ; Cesano A
    PLoS One; 2010 Oct; 5(10):e13543. PubMed ID: 21048955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
    Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
    Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.
    Moharram SA; Chougule RA; Su X; Li T; Sun J; Zhao H; Rönnstrand L; Kazi JU
    Oncotarget; 2016 Sep; 7(36):57770-57782. PubMed ID: 27458164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting RIPK1 in AML cells carrying FLT3-ITD.
    Hillert LK; Bettermann-Bethge K; Nimmagadda SC; Fischer T; Naumann M; Lavrik IN
    Int J Cancer; 2019 Sep; 145(6):1558-1569. PubMed ID: 30828789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activation mechanisms of STAT5 by oncogenic Flt3-ITD.
    Choudhary C; Brandts C; Schwable J; Tickenbrock L; Sargin B; Ueker A; Böhmer FD; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2007 Jul; 110(1):370-4. PubMed ID: 17356133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
    Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
    Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
    Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
    Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.